These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35900700)

  • 1. Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.
    Crispino F; Grova M; Bruno EM; Monachino N; Rizzo G; Casà A; Renna S; Macaluso FS; Orlando A
    Drugs; 2022 Jul; 82(11):1151-1163. PubMed ID: 35900700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seronegative spondyloarthropathy-associated inflammatory bowel disease.
    Wang CR; Tsai HW
    World J Gastroenterol; 2023 Jan; 29(3):450-468. PubMed ID: 36688014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases.
    Felice C; Pugliese D; Papparella LG; Pizzolante F; Onori E; Gasbarrini A; Rapaccini GL; Guidi L; Armuzzi A
    Expert Rev Clin Immunol; 2018 Sep; 14(9):751-759. PubMed ID: 30118354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: A scoping literature review.
    Jubber A; Tahir H; Moorthy A
    Musculoskeletal Care; 2023 Dec; 21(4):1195-1203. PubMed ID: 37501580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease.
    Ben Nessib D; Ferjani H; Maatallah K; Rahmouni S; Kaffel D; Hamdi W
    Clin Rheumatol; 2020 Dec; 39(12):3543-3553. PubMed ID: 32424656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors.
    Subramaniam K; Tymms K; Shadbolt B; Pavli P
    Intern Med J; 2015 Nov; 45(11):1154-60. PubMed ID: 26337851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease.
    Turkcapar N; Toruner M; Soykan I; Aydintug OT; Cetinkaya H; Duzgun N; Ozden A; Duman M
    Rheumatol Int; 2006 May; 26(7):663-8. PubMed ID: 16136311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal lesions associated with spondyloarthropathies.
    Orlando A; Renna S; Perricone G; Cottone M
    World J Gastroenterol; 2009 May; 15(20):2443-8. PubMed ID: 19468992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.
    Cozzi G; Scagnellato L; Lorenzin M; Savarino E; Zingone F; Ometto F; Favero M; Doria A; Vavricka SR; Ramonda R
    Nat Rev Rheumatol; 2023 Aug; 19(8):503-518. PubMed ID: 37386288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment.
    Fragoulis GE; Liava C; Daoussis D; Akriviadis E; Garyfallos A; Dimitroulas T
    World J Gastroenterol; 2019 May; 25(18):2162-2176. PubMed ID: 31143068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
    Dubash S; Marianayagam T; Tinazzi I; Al-Araimi T; Pagnoux C; Weizman AV; Richette P; Tran Minh ML; Allez M; Singh A; Ciccia F; Hamlin J; Tan AL; Marzo-Ortega H; McGonagle D
    Rheumatology (Oxford); 2019 Jun; 58(6):963-968. PubMed ID: 30204909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
    Braun J; Kiltz U; Heldmann F; Baraliakos X
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging treatment options for spondyloarthritis.
    Torgutalp M; Poddubnyy D
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease.
    Luchetti MM; Ciccia F; Avellini C; Benfaremo D; Guggino G; Farinelli A; Ciferri M; Rossini M; Svegliati S; Spadoni T; Bolognini L; Fava G; Mosca P; Gesuita R; Skrami E; Triolo G; Gabrielli A
    J Rheumatol; 2018 May; 45(5):630-637. PubMed ID: 29419466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Macaluso FS; Fries W; Viola A; Costantino G; Muscianisi M; Cappello M; Guida L; Giuffrida E; Magnano A; Pluchino D; Ferracane C; Magrì G; Di Mitri R; Mocciaro F; Privitera AC; Camilleri S; Garufi S; Renna S; Casà A; Scrivo B; Ventimiglia M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1381-1384. PubMed ID: 32981373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The joint-gut axis in inflammatory bowel diseases.
    Brakenhoff LK; van der Heijde DM; Hommes DW; Huizinga TW; Fidder HH
    J Crohns Colitis; 2010 Sep; 4(3):257-68. PubMed ID: 21122514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
    Ward MM; Deodhar A; Akl EA; Lui A; Ermann J; Gensler LS; Smith JA; Borenstein D; Hiratzka J; Weiss PF; Inman RD; Majithia V; Haroon N; Maksymowych WP; Joyce J; Clark BM; Colbert RA; Figgie MP; Hallegua DS; Prete PE; Rosenbaum JT; Stebulis JA; van den Bosch F; Yu DT; Miller AS; Reveille JD; Caplan L
    Arthritis Rheumatol; 2016 Feb; 68(2):282-98. PubMed ID: 26401991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extraskeletal Manifestations in Axial Spondyloarthritis Are Associated With Worse Clinical Outcomes Despite the Use of Tumor Necrosis Factor Inhibitor Therapy.
    van der Meer R; Arends S; Kruidhof S; Bos R; Bootsma H; Wink F; Spoorenberg A
    J Rheumatol; 2022 Feb; 49(2):157-164. PubMed ID: 34393101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.